)
Guardant Health (GH) investor relations material
Guardant Health Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Portfolio momentum and Guardant360
Guardant360 volume growth remained nearly 30%; Guardant Reveal grew over 100% YoY, while Shield volumes reached roughly 3x.
Next year, a complete launch of FDA-approved Guardant360 Liquid CDx is expected to support further volume growth.
Eleven new Smart Apps launched, including blood-based PD-L1 characterization and immune checkpoint inhibitor prediction; additional launches are planned next year.
The Smart Apps platform draws on real-world evidence from hundreds of thousands of patients with EMR, claims and outcomes data.
SERENA-6-related breast cancer testing is starting to lift volumes; physician education continues with AstraZeneca and advocacy groups.
Therapy monitoring and tissue testing
Nearly 1 million late-stage patients may require therapy selection and repeated response monitoring, representing millions of potential U.S. tests.
Guardant360 genomic profiling may be repeated at each cancer progression as tumors evolve and treatment options change.
Guardant360 Tissue combines genomics, transcriptomics and methylation, uses less tissue and has low QNS rates; Q2-to-Q3 growth was its largest sequential increase to date.
FDA approval for Guardant360 Tissue is targeted for next year; management expects approval and the full Liquid CDx launch to support growth and higher tissue-liquid attachment.
Longer term, management expects therapy response monitoring and MRD markets to converge as metastatic drugs move earlier in treatment.
MRD and biopharma data
Guardant Reveal and Reveal Ultra are positioned for distinct MRD needs: tissue-free speed and broader tumor detection, and tumor-informed ultra-sensitive testing.
Thousands of samples are being run to support clinical-validity studies across major tumor types; data will be presented as it becomes ready.
Biopharma work is a fast-growing segment, spanning trial testing, patient monitoring and early treatment-response readouts at 4, 8 and 12 weeks.
Data and methylation capabilities may help pharma segment patients for drugs without traditional genomic biomarkers; management sees growth opportunities in coming years.
- Q3 growth lifted FY2026 guidance as Oncology and Shield screening accelerated.GH
Q3 2026 - Shield’s rapid scale-up, cost reductions, and broad coverage drive strong growth and market leadership.GH
Morgan Stanley 24th Annual Global Healthcare Conference - Rapid growth in oncology diagnostics and payer coverage drive strong momentum and future expansion.GH
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 revenue up 44% to $335M; guidance raised as Shield and oncology volumes surged.GH
Q2 2026 - Multi-cancer early detection is poised to transform cancer care, reducing mortality and costs.GH
7th Annual Healthcare Symposium - Strong growth and innovation, with regulatory and commercial catalysts set to drive 2026 performance.GH
TD Cowen 46th Annual Health Care Conference - 2025 revenue up 33% year-over-year, with robust outlook and innovation driving 2026 growth.GH
Q4 2025 - 2028 revenue target raised to ~$2.2B, with accelerated breakeven and major product launches.GH
Investor Day 2025 - Q3 revenue up 34% to $191.5M; Shield launch, ASP gains, and raised guidance highlight growth.GH
Q3 2024
)
)
)
)
)
)
)
)